Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast

The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline). We anticipate that the angiogenesis and PARP inhibitor stronghold will continue throughout the forecast period, principally as part of combination regimens with immune checkpoint inhibitors. The late-phase pipeline for ovarian cancer has expanded in recent years and spans a variety of drug classes. Several novel therapies are set to enter the ovarian cancer market and diversify treatment options.

Questions answered

  • What is the size of clinically and commercially relevant drug-treatable ovarian cancer populations, and how will drug-treatment rates change over time?
  • What is the current state of treatment for ovarian cancer?
  • What are the most promising agents in the pipeline, and how will they shape the future of the ovarian cancer therapy market?
  • What are the main drivers of and constraints in the ovarian cancer market, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • November 2021
      • Q3 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
    • Key Findings
      • Market Outlook
        • Key Findings
          • Market Share of Ovarian Cancer Drug Classes: 2020
          • Market Share of Ovarian Cancer Drug Classes: 2030
          • Drug-Treatable Population Share and Major-Market Sales Share in Ovarian Cancer: 2020
          • Drug-Treatable Population Share and Major-Market Sales Share in Ovarian Cancer: 2030
          • Population Positioning of Therapies in Ovarian Cancer: United States
          • Population Positioning of Therapies in Ovarian Cancer: Europe
          • Population Positioning of Therapies in Ovarian Cancer: Japan
          • Ovarian Cancer SWOT Analysis
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Ovarian Cancer?
          • What Factors Are Constraining the Market for Ovarian Cancer?
          • Major-Market Sales for Ovarian Cancer by Region: 2020-2030
          • Major-Market Sales for Ovarian Cancer by Drug Class: 2020-2030
          • Major-Market Sales of Targeted Therapies in the Ovarian Cancer Market: 2020-2030
          • Share of PARP Inhibitors by Patient Population in the Major Markets: 2020-2030
        • Segment-Specific Trends
          • Patient-Share Dynamics of Key Therapies (Excluding Maintenance) in First-Line Advanced-Stage Ovarian Cancer in the United States: 2020-2030
          • Patient-Share Dynamics of Maintenance Therapies in First-Line Advanced-Stage Ovarian Cancer in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies Excluding Maintenance Treatments in the Second-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2020-2030
          • Patient-Share Dynamics of Maintenance Therapies in the Second-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies Excluding Maintenance Treatments in the Third-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2020-2030
          • Patient-Share Dynamics of Maintenance Therapies in the Third-Line Platinum-Sensitive Ovarian Cancer Setting in the United States: 2020-2030
          • Patient-Share Dynamics of Second-Line Platinum-Resistant and Platinum-Refractory Ovarian Cancer in the United States: 2020-2030
          • Patient-Share Dynamics of Third-Line Platinum-Resistant and Platinum-Refractory Ovarian Cancer Setting in the United States: 2020-2030
          • Patient-Share Dynamics of Key Therapies in the Fourth- and Subsequent-Line Ovarian Cancer Setting in the United States: 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Disease Pathophysiology
            • Disease Pathogenesis
            • Disease Classification
            • Ovarian Cancer Histologies
            • Molecular Subtypes and Key Pathways
            • Screening Tests: CA-125
          • Staging and Classification
            • Staging and Grading
            • International Federation of Gynecology and Obstetrics Staging System for Cancer of the Ovary, Fallopian Tube, and Peritoneum
            • Stage I-II
            • Stage III-IV
          • Key Pathways and Drug Targets
            • Key Pathways and Drug Targets for Ovarian Cancer
            • Key Signaling Pathways in Epithelial Cells
            • PARP Inhibition: Mechanism of Action
            • Folate Receptor Pathway
            • Immune Checkpoint Inhibitors and Modulators
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Diagnosed Incidence of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
              • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: 2020-2030
              • Contributing Proportion of Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers in 2020
              • Disease Definition
              • Methods
              • Sources Used for Stage at Diagnosis of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
              • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer by Stage: 2020-2030
              • Stage Distribution of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in the Major Mature Markets in 2020
              • Disease Definition
              • Methods
              • Sources Used for BRCA Mutations in Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
              • Diagnosed Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer by BRCA Mutation: 2020-2030
              • Disease Definition
              • Methods
              • Sources Used for Recurrent Incidence of Epithelial Ovarian and Fallopian Tube Cancer
              • Recurrent Incident Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2020-2030
              • Ovarian Cancer Patient Flow
              • Drug-Treatable Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2020-2030
              • Drug-Treated Cases of Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer: 2020-2030
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Ovarian Cancer
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes
                • Current Treatments Used for Ovarian Cancer
                • Market Events Impacting the Use of Key Current Therapies in Ovarian Cancer
                • Advantages and Disadvantages of Bevacizumab
                • Key Results From Clinical Trials Investigating Bevacizumab for the Treatment of Ovarian Cancer
                • Ongoing Clinical Development
                • Key Ongoing Clinical Trials of Bevacizumab in the Treatment of Ovarian Cancer
                • Expert Insight: Bevacizumab
                • Advantages and Disadvantages of Lynparza
                • Key Results From Clinical Trials Investigating Lynparza for the Treatment of Ovarian Cancer
                • Ongoing Clinical Development
                • Key Ongoing Clinical Trials of Lynparza in the Treatment of Ovarian Cancer
                • Expert Insight: Lynparza
                • Advantages and Disadvantages of Rubraca
                • Key Results From Clinical Trials Investigating Rubraca for the Treatment of Ovarian Cancer
                • Ongoing Clinical Development
                • Key Ongoing Clinical Trials Investigating Rubraca in the Treatment of Ovarian Cancer
                • Expert Insight: Rubraca
                • Advantages and Disadvantages of Zejula
                • Key Results From Clinical Trials Investigating Zejula for the Treatment of Ovarian Cancer
                • Ongoing Clinical Development
                • Key Ongoing Clinical Trials Investigating Zejula in the Treatment of Ovarian Cancer
                • Expert Insight: Zejula
                • Key Results From Clinical Trials Investigating Yondelis for the Treatment of Ovarian Cancer
                • Ongoing Clinical Development
              • Medical Practice
                • Early-Stage First-Line Ovarian Cancer
                • Advanced-Stage First-Line Ovarian Cancer
                • Second- and Third-Line Platinum-Sensitive Ovarian Cancer
                • Second- and Third-Line Platinum-Resistant and -Refractory Ovarian Cancer
                • Fourth- and Subsequent-Line Ovarian Cancer
                • Country-Specific Ovarian Cancer Treatment Guidelines
                • Patient Characteristics Influencing Drug Selection in Ovarian Cancer
                • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: United States
                • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: Europe
                • Treatment Decision Tree for Early- and Advanced-Stage Ovarian Cancer: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Ovarian Cancer
              • Top Unmet Needs in Ovarian Cancer: Current and Future Attainment
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Therapies in Late-Phase Development for Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Veliparib for the Treatment of Ovarian Cancer
                  • Veliparib Clinical Development
                  • Expert Insight: Veliparib
                  • Expectations for Launch and Sales Opportunity of Veliparib in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Tecentriq for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Tecentriq in the Treatment of Ovarian Cancer
                  • Tecentriq Clinical Development
                  • Expert Insight: Tecentriq
                  • Expectations for Market Authorization and Sales Opportunity of Tecentriq in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Keytruda for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Keytruda in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Keytruda
                  • Expert Insight: Keytruda
                  • Expectations for Market Authorization and Sales Opportunity of Keytruda in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Opdivo in the Treatment of Ovarian Cancer
                  • Opdivo Clinical Development
                  • Expert Insight: Opdivo
                  • Expectations for Market Authorization and Sales Opportunity of Opdivo in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Imfinzi for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Imfinzi in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Imfinzi
                  • Expert Insight: Imfinzi
                  • Expectations for the Launch and Sales Opportunity of Imfinzi in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Jemperli for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Jemperli in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Jemperli
                  • Expert Insight: Jemperli
                  • Expectations for Launch and Sales Opportunity of Jemperli in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Olvimulogene Nanivacirepvec for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Ofranergene Obadenovec in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Olvimulogene Nanivacirepvec
                  • Expectations for Market Authorization and Sales Opportunity of Olvimulogene Nanivacirepvec in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating DCVAC/OvCa for the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of DCVAC/OvCa
                  • Expert Insight: DCVAC/OvCa
                  • Expectations for Market Authorization and Sales Opportunity of DCVAC/OvCa in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Cediranib for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Cediranib for the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Cediranib
                  • Expert Insight: Cediranib
                  • Expectations for Launch and Sales Opportunity of Cediranib in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Ofranergene Obadenovec for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Ofranergene Obadenovec in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Ofranergene Obadenovec
                  • Expert Insight: Ofranergene Obadenovec
                  • Expectations for Launch and Sales Opportunity of Ofranergene Obadenovec in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Relacorilant in Ovarian Cancer
                  • Key Ongoing Clinical Trials of Relacorilant for the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Relacorilant
                  • Expectation for Market Authorization of Relacorilant
                  • Key Results From Select Clinical Trials Investigating Oregovomab in Ovarian Cancer
                  • Key Ongoing Clinical Trials of Oregovomab for the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Oregovomab
                  • Expert Insight: Oregovomab
                  • Expectation for Market Authorization of Oregovomab
                  • Key Results From Select Clinical Trials Investigating Piqray in Ovarian Cancer
                  • Key Ongoing Clinical Trials of Piqray for the Treatment of Ovarian Cancer
                  • Analysis of the Clinical Development Program for Piqray
                  • Expectation for Market Authorization and Sales Opportunity of Piqray in Ovarian cancer
                  • Key Results From Select Clinical Trials Investigating AVB-500 in Ovarian Cancer
                  • Key Ongoing Clinical Trials of AVB-500 for the Treatment of Ovarian Cancer
                  • Analysis of the Clinical Development Program for AVB-500
                  • Expectation for Market Authorization and Sales Opportunity of AVB-500 in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Nemvaleukin Alfa for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Nemvaleukin Alfa in Ovarian Cancer
                  • Analysis of the Clinical Development Program for Nemvaleukin Alfa
                  • Expectations for Market Authorization and Sales Opportunity of Nemvaleukin Alfa in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Upifitamab Rilsodotin in Ovarian Cancer
                  • Key Ongoing Clinical Trials of Upifitamab Rilsodotin in Ovarian Cancer
                  • Analysis of the Clinical Development Program for Upifitamab Rilsodotin
                  • Expert Insight: Upfitamab Rilsodotin
                  • Expectation for Market Authorization and Sales Opportunity of Upifitamab Rilsodotin in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Mirvetuximab Soravtansine for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Mirvetuximab Soravtansine in the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Mirvetuximab Soravtansine
                  • Expert Insight: Mirvetuximab Soravtansine
                  • Expectations for Launch and Sales Opportunity of Mirvetuximab Soravtansine in Ovarian Cancer
                  • Key Results From Clinical Trials Investigating Navicixizumab for the Treatment of Ovarian Cancer
                  • Key Ongoing Clinical Trials of Navicixizumab in Ovarian Cancer
                  • Analysis of the Clinical Development Program for Navicixizumab
                  • Expert Insight: Navicixizumab
                  • Expectation for Market Authorization and Sales Opportunity of Navicixizumab in Ovarian Cancer
                  • Key Results From Select Clinical Trials Investigating Mekinist for the Treatment of Ovarian Cancer
                  • Ongoing Clinical Development of Mekinist
                  • Expert Insight: Mekinist
                  • Expectations for Launch and Sales Opportunity of Mekinist in Ovarian Cancer
                • Early-Phase Pipeline Analysis
                  • Select Compounds in Phase I/II Development for Ovarian Cancer
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Ovarian Cancer: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Ovarian Cancer: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Ovarian Cancer: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Ovarian Cancer Bibliography